Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

12 octobre 2026 mis à jour par: AbbVie

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer

Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.

ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.

In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

285

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • New South Wales
      • Blacktown, New South Wales, Australie, 2148
        • Recrutement
        • Blacktown Hospital /ID# 282426
    • Victoria
      • Clayton, Victoria, Australie, 3168
        • Recrutement
        • Monash Health - Monash Medical Centre - Clayton /ID# 281468
      • Melbourne, Victoria, Australie, 3000
        • Recrutement
        • Peter MacCallum Cancer Centre. /ID# 281751
      • Barcelona, Espagne, 08035
        • Recrutement
        • Hospital Universitari Vall d Hebron /ID# 280442
      • Madrid, Espagne, 28040
        • Recrutement
        • Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
      • Madrid, Espagne, 28050
        • Recrutement
        • Hospital Universitario HM Sanchinarro /ID# 280439
    • Madrid
      • Majadahonda, Madrid, Espagne, 28222
        • Recrutement
        • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, France, 44805
        • Recrutement
        • Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
    • Rhone
      • Lyon, Rhone, France, 69373
        • Recrutement
        • Centre Leon Berard /ID# 280575
      • Haifa, Israël, 3109601
        • Recrutement
        • Rambam Health Care Campus /ID# 278418
      • Jerusalem, Israël, 91120
        • Recrutement
        • Hadassah Medical Center-Hebrew University /ID# 278420
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israël, 5265601
        • Recrutement
        • The Chaim Sheba Medical Center /ID# 278416
    • Chiba
      • Kashiwa-shi, Chiba, Japon, 277-8577
        • Recrutement
        • National Cancer Center Hospital East /ID# 278604
    • Saitama
      • Hidaka, Saitama, Japon, 350-1298
        • Recrutement
        • Saitama Medical University International Medical Center /ID# 278437
    • Shizuoka
      • Sunto-gun, Shizuoka, Japon, 411-8777
        • Recrutement
        • Shizuoka Cancer Center /ID# 278538
      • Lisbon, Le Portugal, 1649-035
        • Recrutement
        • Unidade Local de Saude de Santa Maria /ID# 280296
      • Porto, Le Portugal, 4200-072
        • Recrutement
        • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
      • Taipei, Taïwan, 112
        • Recrutement
        • Taipei Veterans General Hospital /ID# 281349
      • Taipei, Taïwan, 100
        • Recrutement
        • National Taiwan University Hospital /ID# 280701
    • California
      • Duarte, California, États-Unis, 91010
        • Recrutement
        • City of Hope National Medical Center /ID# 281381
      • Irvine, California, États-Unis, 92618
        • Recrutement
        • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
    • Colorado
      • Denver, Colorado, États-Unis, 80218
        • Recrutement
        • Sarah Cannon Research Institute at HealthONE /ID# 278785
    • Illinois
      • Chicago, Illinois, États-Unis, 60637
        • Recrutement
        • University of Chicago Medical Center /ID# 278295
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68198
        • Recrutement
        • University Of Nebraska Medical Center /ID# 281020
    • Texas
      • San Antonio, Texas, États-Unis, 78229
        • Recrutement
        • NEXT Oncology - San Antonio /ID# 278606
    • Utah
      • West Valley City, Utah, États-Unis, 84119
        • Recrutement
        • Start Mountain Region /ID# 278609
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Recrutement
        • Next Virginia /ID# 278607

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
  • Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.

For Parts 1-4:

- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).

For Parts 5-6:

- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.

Exclusion Criteria:

  • Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
  • Participants with platinum refractory disease.
  • Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
  • Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
  • Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.

For Parts 3-6:

  • History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
  • History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
  • Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.

For Parts 5-6:

- Participants who had prior allergic reaction to platinum containing compound.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1: ABBV-901 Dose Escalation

Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Expérimental: Part 2: ABBV-901 Optimization Dose A

Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Expérimental: Part 2: ABBV-901 Optimization Dose B

Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Expérimental: Part 2: ABBV-901 Optimization Dose C

Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Expérimental: Part 3: ABBV-901 + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Expérimental: Part 4: ABBV-901 + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Expérimental: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

Expérimental: Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants with Adverse Events (AE)
Délai: Up to Approximately 3 Years

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

Up to Approximately 3 Years
Overall Response (as assessed by the investigator)
Délai: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.

Up to Approximately 3 Years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Response (as assessed by independent central review)
Délai: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR).

Up to Approximately 3 Years
Duration of Response (DOR)
Délai: Up to Approximately 3 Years

DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.

Up to Approximately 3 Years
Progression-free survival (PFS)
Délai: Up to Approximately 3 Years

PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier.

Up to Approximately 3 Years
Overall Survival (OS)
Délai: Up to Approximately 3 Years

OS is defined as time from first study treatment to death due to any cause.

Up to Approximately 3 Years
Disease Control Rate
Délai: Up to Approximately 3 Years

Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria.

Up to Approximately 3 Years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: ABBVIE INC., AbbVie

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 novembre 2025

Achèvement primaire (Estimé)

1 décembre 2028

Achèvement de l'étude (Estimé)

1 janvier 2029

Dates d'inscription aux études

Première soumission

2 décembre 2025

Première soumission répondant aux critères de contrôle qualité

2 décembre 2025

Première publication (Réel)

12 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner